CytomX Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
CytomX Therapeutics, Inc. (CTMX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$23.38 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-09
- CytomX Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$23.38M.
- CytomX Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$149.76M, a 452.79% decline year-over-year.
- CytomX Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $15.94M, a 40.96% increase year-over-year.
- CytomX Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $13.34M.
- CytomX Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$121.27M, a 364.43% decline from fiscal 2016.
- CytomX Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $45.86M.
- CytomX Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$130.56M.
- CytomX Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$1.66M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$23.38M 10-Q · filed 2018-05-09 | -$173.14M derived: sum of 2 quarters · filed 2018-05-09 | -$157.20M derived: sum of 3 quarters · filed 2018-05-09 | -$143.86M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | -$149.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$133.81M derived: sum of 2 quarters · filed 2018-03-07 | -$120.48M derived: sum of 3 quarters · filed 2018-03-07 | -$121.27M 10-K · filed 2018-03-07 |
| 2017-09-30 | $15.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $29.28M derived: sum of 2 quarters · filed 2017-11-07 | $28.49M 10-Q · filed 2017-11-07 | $70.94M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-06-30 | $13.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $12.55M 10-Q · filed 2017-08-07 | $55.00M derived: sum of 3 quarters · filed 2018-05-09 | $66.31M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-03-31 | -$788.00K 10-Q · filed 2018-05-09 | $41.66M derived: sum of 2 quarters · filed 2018-05-09 | $52.97M derived: sum of 3 quarters · filed 2018-05-09 | $31.49M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $42.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $53.76M derived: sum of 2 quarters · filed 2018-03-07 | $32.28M derived: sum of 3 quarters · filed 2018-03-07 | $45.86M 10-K · filed 2018-03-07 |
| 2016-09-30 | $11.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$10.17M derived: sum of 2 quarters · filed 2017-11-07 | $3.41M 10-Q · filed 2017-11-07 | -$47.44M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | -$21.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$7.90M 10-Q · filed 2017-08-07 | -$58.75M derived: sum of 3 quarters · filed 2018-03-07 | -$57.45M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $13.58M 10-Q · filed 2017-05-05 | -$37.27M derived: sum of 2 quarters · filed 2018-03-07 | -$35.97M derived: sum of 3 quarters · filed 2018-03-07 | -$64.94M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | -$50.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$49.55M derived: sum of 2 quarters · filed 2018-03-07 | -$78.52M derived: sum of 3 quarters · filed 2018-03-07 | -$130.56M 10-K · filed 2018-03-07 |
| 2015-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$27.67M derived: sum of 2 quarters · filed 2016-11-03 | -$79.72M 10-Q · filed 2016-11-03 | -$80.38M derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-06-30 | -$28.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$81.01M 10-Q · filed 2016-08-03 | -$81.68M derived: sum of 3 quarters · filed 2017-03-02 | |
| 2015-03-31 | -$52.04M 10-Q · filed 2016-05-06 | -$52.71M derived: sum of 2 quarters · filed 2017-03-02 | ||
| 2014-12-31 | -$664.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | -$1.66M 10-K · filed 2017-03-02 | ||
| 2014-09-30 | -$999.00K 10-Q · filed 2015-11-23 | |||
| 2013-12-31 | -$732.00K 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |